Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 13 to 18 of 18 entries
Sorted by: Best Match Show Resources per page
Nanotetrac targets integrin αvβ3 on tumor cells to disorder cell defense pathways and block angiogenesis.

OncoTargets and therapy

Davis PJ, Lin HY, Sudha T, Yalcin M, Tang HY, Hercbergs A, Leith JT, Luidens MK, Ashur-Fabian O, Incerpi S, Mousa SA.
PMID: 25258542
Onco Targets Ther. 2014 Sep 18;7:1619-24. doi: 10.2147/OTT.S67393. eCollection 2014.

The extracellular domain of integrin αvβ3 contains a receptor for thyroid hormone and hormone analogs. The integrin is amply expressed by tumor cells and dividing blood vessel cells. The proangiogenic properties of thyroid hormone and the capacity of the...

Cite
Davis PJ, Lin HY, Sudha T, et al. Nanotetrac targets integrin αvβ3 on tumor cells to disorder cell defense pathways and block angiogenesis. Onco Targets Ther. 2014;7:1619-24doi: 10.2147/OTT.S67393.
Davis, P. J., Lin, H. Y., Sudha, T., Yalcin, M., Tang, H. Y., Hercbergs, A., Leith, J. T., Luidens, M. K., Ashur-Fabian, O., Incerpi, S., & Mousa, S. A. (2014). Nanotetrac targets integrin αvβ3 on tumor cells to disorder cell defense pathways and block angiogenesis. OncoTargets and therapy, 71619-24. https://doi.org/10.2147/OTT.S67393
Davis, Paul J, et al. "Nanotetrac targets integrin αvβ3 on tumor cells to disorder cell defense pathways and block angiogenesis." OncoTargets and therapy vol. 7 (2014): 1619-24. doi: https://doi.org/10.2147/OTT.S67393
Davis PJ, Lin HY, Sudha T, Yalcin M, Tang HY, Hercbergs A, Leith JT, Luidens MK, Ashur-Fabian O, Incerpi S, Mousa SA. Nanotetrac targets integrin αvβ3 on tumor cells to disorder cell defense pathways and block angiogenesis. Onco Targets Ther. 2014 Sep 18;7:1619-24. doi: 10.2147/OTT.S67393. eCollection 2014. PMID: 25258542; PMCID: PMC4172128.
Copy Download .nbib Format: NLM
Corrigendum: "Cancer Cell Gene Expression Modulated from Plasma Membrane Integrin αvβ3 by Thyroid Hormone and Nanoparticulate Tetrac".

Frontiers in endocrinology

Davis PJ, Glinsky GV, Lin HY, Leith JT, Hercbergs A, Tang HY, Ashur-Fabian O, Incerpi S, Mousa SA.
PMID: 26106368
Front Endocrinol (Lausanne). 2015 Jun 09;6:98. doi: 10.3389/fendo.2015.00098. eCollection 2015.

[This corrects the article on p. 240 in vol. 5, PMID: 25628605.].

Cite
Davis PJ, Glinsky GV, Lin HY, et al. Corrigendum: "Cancer Cell Gene Expression Modulated from Plasma Membrane Integrin αvβ3 by Thyroid Hormone and Nanoparticulate Tetrac". Front Endocrinol (Lausanne). 2015;6:98doi: 10.3389/fendo.2015.00098.
Davis, P. J., Glinsky, G. V., Lin, H. Y., Leith, J. T., Hercbergs, A., Tang, H. Y., Ashur-Fabian, O., Incerpi, S., & Mousa, S. A. (2015). Corrigendum: "Cancer Cell Gene Expression Modulated from Plasma Membrane Integrin αvβ3 by Thyroid Hormone and Nanoparticulate Tetrac". Frontiers in endocrinology, 698. https://doi.org/10.3389/fendo.2015.00098
Davis, Paul J, et al. "Corrigendum: "Cancer Cell Gene Expression Modulated from Plasma Membrane Integrin αvβ3 by Thyroid Hormone and Nanoparticulate Tetrac"." Frontiers in endocrinology vol. 6 (2015): 98. doi: https://doi.org/10.3389/fendo.2015.00098
Davis PJ, Glinsky GV, Lin HY, Leith JT, Hercbergs A, Tang HY, Ashur-Fabian O, Incerpi S, Mousa SA. Corrigendum: "Cancer Cell Gene Expression Modulated from Plasma Membrane Integrin αvβ3 by Thyroid Hormone and Nanoparticulate Tetrac". Front Endocrinol (Lausanne). 2015 Jun 09;6:98. doi: 10.3389/fendo.2015.00098. eCollection 2015. PMID: 26106368; PMCID: PMC4460813.
Copy Download .nbib Format: NLM
Thyroid Hormones and Cancer: A Comprehensive Review of Preclinical and Clinical Studies.

Frontiers in endocrinology

Krashin E, Piekiełko-Witkowska A, Ellis M, Ashur-Fabian O.
PMID: 30814976
Front Endocrinol (Lausanne). 2019 Feb 13;10:59. doi: 10.3389/fendo.2019.00059. eCollection 2019.

Thyroid hormones take major part in normal growth, development and metabolism. Over a century of research has supported a relationship between thyroid hormones and the pathophysiology of various cancer types.

Cite
Krashin E, Piekiełko-Witkowska A, Ellis M, et al. Thyroid Hormones and Cancer: A Comprehensive Review of Preclinical and Clinical Studies. Front Endocrinol (Lausanne). 2019;10:59doi: 10.3389/fendo.2019.00059.
Krashin, E., Piekiełko-Witkowska, A., Ellis, M., & Ashur-Fabian, O. (2019). Thyroid Hormones and Cancer: A Comprehensive Review of Preclinical and Clinical Studies. Frontiers in endocrinology, 1059. https://doi.org/10.3389/fendo.2019.00059
Krashin, Eilon, et al. "Thyroid Hormones and Cancer: A Comprehensive Review of Preclinical and Clinical Studies." Frontiers in endocrinology vol. 10 (2019): 59. doi: https://doi.org/10.3389/fendo.2019.00059
Krashin E, Piekiełko-Witkowska A, Ellis M, Ashur-Fabian O. Thyroid Hormones and Cancer: A Comprehensive Review of Preclinical and Clinical Studies. Front Endocrinol (Lausanne). 2019 Feb 13;10:59. doi: 10.3389/fendo.2019.00059. eCollection 2019. PMID: 30814976; PMCID: PMC6381772.
Copy Download .nbib Format: NLM
Nuclear αvβ3 integrin expression, post translational modifications and regulation in hematological malignancies.

Hematological oncology

Weisz A, Abadi U, Mausbach L, Gurwitz D, Ellis M, Ashur-Fabian O.
PMID: 34534368
Hematol Oncol. 2021 Sep 17; doi: 10.1002/hon.2927. Epub 2021 Sep 17.

αvβ3 integrin, a plasma membrane protein, is amply expressed on an array of tumors. We identified nuclear αvβ3 pool in ovarian cancer cells and were interested to explore this phenomenon in two rare and aggressive types of leukemia, T-cell...

Cite
Weisz A, Abadi U, Mausbach L, et al. Nuclear αvβ3 integrin expression, post translational modifications and regulation in hematological malignancies. Hematol Oncol. 2021;doi: 10.1002/hon.2927.
Weisz, A., Abadi, U., Mausbach, L., Gurwitz, D., Ellis, M., & Ashur-Fabian, O. (2021). Nuclear αvβ3 integrin expression, post translational modifications and regulation in hematological malignancies. Hematological oncology, . https://doi.org/10.1002/hon.2927
Weisz, Avivit, et al. "Nuclear αvβ3 integrin expression, post translational modifications and regulation in hematological malignancies." Hematological oncology vol. (2021). doi: https://doi.org/10.1002/hon.2927
Weisz A, Abadi U, Mausbach L, Gurwitz D, Ellis M, Ashur-Fabian O. Nuclear αvβ3 integrin expression, post translational modifications and regulation in hematological malignancies. Hematol Oncol. 2021 Sep 17; doi: 10.1002/hon.2927. Epub 2021 Sep 17. PMID: 34534368.
Copy Download .nbib Format: NLM
Pre-diagnosis thyroid hormone dysfunction is associated with cancer mortality.

Endocrine-related cancer

Krashin E, Silverman B, Steinberg DM, Yekutieli D, Giveon S, Fabian O, Hercbergs A, Davis PJ, Ellis M, Ashur-Fabian O.
PMID: 34432646
Endocr Relat Cancer. 2021 Sep 20;28(11):705-713. doi: 10.1530/ERC-21-0187.

Research on the association between thyroid hormone levels and cancer mortality remains limited and inconclusive. We determined the relation of thyroid stimulating hormone (TSH), free T4 (FT4), and free T3 (FT3) levels with mortality in overall cancer and specific...

Cite
Krashin E, Silverman B, Steinberg DM, et al. Pre-diagnosis thyroid hormone dysfunction is associated with cancer mortality. Endocr Relat Cancer. 2021;28(11):705-713doi: 10.1530/ERC-21-0187.
Krashin, E., Silverman, B., Steinberg, D. M., Yekutieli, D., Giveon, S., Fabian, O., Hercbergs, A., Davis, P. J., Ellis, M., & Ashur-Fabian, O. (2021). Pre-diagnosis thyroid hormone dysfunction is associated with cancer mortality. Endocrine-related cancer, 28(11), 705-713. https://doi.org/10.1530/ERC-21-0187
Krashin, Eilon, et al. "Pre-diagnosis thyroid hormone dysfunction is associated with cancer mortality." Endocrine-related cancer vol. 28,11 (2021): 705-713. doi: https://doi.org/10.1530/ERC-21-0187
Krashin E, Silverman B, Steinberg DM, Yekutieli D, Giveon S, Fabian O, Hercbergs A, Davis PJ, Ellis M, Ashur-Fabian O. Pre-diagnosis thyroid hormone dysfunction is associated with cancer mortality. Endocr Relat Cancer. 2021 Sep 20;28(11):705-713. doi: 10.1530/ERC-21-0187. PMID: 34432646.
Copy Download .nbib Format: NLM
Targeting the DIO3 enzyme using first-in-class inhibitors effectively suppresses tumor growth: a new paradigm in ovarian cancer treatment.

Oncogene

Moskovich D, Finkelshtein Y, Alfandari A, Rosemarin A, Lifschytz T, Weisz A, Mondal S, Ungati H, Katzav A, Kidron D, Mugesh G, Ellis M, Lerer B, Ashur-Fabian O.
PMID: 34556811
Oncogene. 2021 Nov;40(44):6248-6257. doi: 10.1038/s41388-021-02020-z. Epub 2021 Sep 23.

The enzyme iodothyronine deiodinase type 3 (DIO3) contributes to cancer proliferation by inactivating the tumor-suppressive actions of thyroid hormone (T3). We recently established DIO3 involvement in the progression of high-grade serous ovarian cancer (HGSOC). Here we provide a link...

Cite
Moskovich D, Finkelshtein Y, Alfandari A, et al. Targeting the DIO3 enzyme using first-in-class inhibitors effectively suppresses tumor growth: a new paradigm in ovarian cancer treatment. Oncogene. 2021;40(44):6248-6257doi: 10.1038/s41388-021-02020-z.
Moskovich, D., Finkelshtein, Y., Alfandari, A., Rosemarin, A., Lifschytz, T., Weisz, A., Mondal, S., Ungati, H., Katzav, A., Kidron, D., Mugesh, G., Ellis, M., Lerer, B., & Ashur-Fabian, O. (2021). Targeting the DIO3 enzyme using first-in-class inhibitors effectively suppresses tumor growth: a new paradigm in ovarian cancer treatment. Oncogene, 40(44), 6248-6257. https://doi.org/10.1038/s41388-021-02020-z
Moskovich, Dotan, et al. "Targeting the DIO3 enzyme using first-in-class inhibitors effectively suppresses tumor growth: a new paradigm in ovarian cancer treatment." Oncogene vol. 40,44 (2021): 6248-6257. doi: https://doi.org/10.1038/s41388-021-02020-z
Moskovich D, Finkelshtein Y, Alfandari A, Rosemarin A, Lifschytz T, Weisz A, Mondal S, Ungati H, Katzav A, Kidron D, Mugesh G, Ellis M, Lerer B, Ashur-Fabian O. Targeting the DIO3 enzyme using first-in-class inhibitors effectively suppresses tumor growth: a new paradigm in ovarian cancer treatment. Oncogene. 2021 Nov;40(44):6248-6257. doi: 10.1038/s41388-021-02020-z. Epub 2021 Sep 23. PMID: 34556811.
Copy Download .nbib Format: NLM
Showing 13 to 18 of 18 entries